Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study (Q33415304)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Filippo de Braud

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Vincenzo Mazzaferro

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

R Buzzoni

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

E Bajetta

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Platania

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

C Iannacone

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

M Cantore

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

A Mambrini

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

A Bertolini

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

O Alabiso

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

A Ciarlo

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

C Turco

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

14 May 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

25

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1597-1603

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827133%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Systemic therapy for biliary tract cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Activated mammalian target of rapamycin is an adverse prognostic factor in patients with biliary tract adenocarcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Targeted therapy for biliary tract cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

The mTOR pathway in hepatic malignancies

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Tumor growth effects of rapamycin on human biliary tract cancer cells

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Management of adverse events associated with the use of everolimus in patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: A large retrospective study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU175

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33415304&oldid=1606853155"